STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #814 by analyst upside · 2026-08-13
CNSP
CNS Pharmaceuticals, Inc.
Healthcare · Market Cap $7M · P/E 0x
ANALYST PRICE TARGET
+99.6%
implied upside to consensus target
Current Price $5.01
Consensus Target $10.0
Bull Target $10.0
Bear Target $10.0
Analysts Covering 1
ANALYST CONSENSUS - STRONG BUY
Strong Buy
1
Buy
0
Hold
0
Sell
0
52-Week Low $1.9
52-Week High $10.59
YTD Return -5.5%
FUNDAMENTALS
Market Cap $7M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-21.97
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.9
52-Week High $10.59
Current Price $5.01
Bear Target $10.0
Bull Target $10.0
● Now $5.01 ● Target $10.0
TRADING DATA
Avg Volume 31K
YTD Return -5.5%
Analyst Count 1
Consensus Strong Buy
Upside to Target +99.6%
Last Updated 2026-08-13

ANALYST SUMMARY

CNS Pharmaceuticals, Inc. (CNSP) is currently trading at $5.01 with a Wall Street consensus price target of $10.0, implying potential upside of 99.6% over the next 12 months. 1 analysts currently cover CNSP, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $10.0.

CNSP operates in the Healthcare sector with a market capitalisation of $7M. The stock is down 5.5% year-to-date and is currently trading near the lower end of its 52-week range of $1.9 – $10.59.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CNSP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Maxim Group ↑ Upgrade
Hold → Buy 2025-09-12 28% win rate (40 calls)
Maxim Group ↓ Downgrade
Buy → Hold 2025-03-25 28% win rate (40 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
5/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →